The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback